Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

Similar articles for PubMed (Select 18779943)

1.

[B-cell-depleting antibodies in skin diseases].

Nagel A, Hertl M, Eming R.

Hautarzt. 2008 Oct;59(10):793-805. doi: 10.1007/s00105-008-1538-7. Review. German.

PMID:
18779943
2.

B-cell-directed therapy for inflammatory skin diseases.

Nagel A, Hertl M, Eming R.

J Invest Dermatol. 2009 Feb;129(2):289-301. doi: 10.1038/jid.2008.192. Review.

3.

Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.

Dörner T.

J Rheumatol Suppl. 2006 May;77:3-11. Review.

PMID:
16652439
4.

B cells move to centre stage: novel opportunities for autoimmune disease treatment.

Browning JL.

Nat Rev Drug Discov. 2006 Jul;5(7):564-76. Review.

PMID:
16816838
5.

[The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].

Thurlings RM, Vos K, Gerlag DM, Tak PP.

Ned Tijdschr Geneeskd. 2006 Jul 29;150(30):1657-61. Review. Dutch.

PMID:
16922350
6.

B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.

Levesque MC, St Clair EW.

J Allergy Clin Immunol. 2008 Jan;121(1):13-21; quiz 22-3. doi: 10.1016/j.jaci.2007.11.030. Review.

PMID:
18206502
7.

[Targeting B cells in multiple sclerosis. Current concepts and strategies].

Menge T, Büdingen HC, Dalakas MC, Kieseier BC, Hartung HP.

Nervenarzt. 2009 Feb;80(2):190-8. doi: 10.1007/s00115-008-2664-2. Review. German.

PMID:
19189075
8.

B-cell targeting: a novel approach to immune intervention today and tomorrow.

Dörner T, Lipsky PE.

Expert Opin Biol Ther. 2007 Sep;7(9):1287-99. Review.

PMID:
17727320
9.
10.

[Autoantibodies and antibody-secreting cells].

Hiepe F, Dörner T.

Z Rheumatol. 2005 Sep;64(6):389-95. Review. German.

PMID:
16184346
11.

B-cell-directed therapies for autoimmune disease.

Dörner T, Radbruch A, Burmester GR.

Nat Rev Rheumatol. 2009 Aug;5(8):433-41. doi: 10.1038/nrrheum.2009.141. Epub 2009 Jul 7. Review.

PMID:
19581902
12.

Regulatory B cells in skin and connective tissue diseases.

Fujimoto M.

J Dermatol Sci. 2010 Oct;60(1):1-7. doi: 10.1016/j.jdermsci.2010.08.010. Epub 2010 Sep 15. Review.

PMID:
20832998
13.

B cells as therapeutic targets in autoimmune neurological disorders.

Dalakas MC.

Nat Clin Pract Neurol. 2008 Oct;4(10):557-67. doi: 10.1038/ncpneuro0901. Epub 2008 Sep 23. Review.

PMID:
18813230
14.

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.

Taylor RP, Lindorfer MA.

Nat Clin Pract Rheumatol. 2007 Feb;3(2):86-95. Review.

PMID:
17299446
15.

[B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].

Tanaka Y.

Yakugaku Zasshi. 2009 Jun;129(6):675-9. Review. Japanese.

16.

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

Liossis SN, Sfikakis PP.

Clin Immunol. 2008 Jun;127(3):280-5. doi: 10.1016/j.clim.2008.01.011. Epub 2008 Mar 11. Review.

PMID:
18337174
17.

B-cell targeting in rheumatoid arthritis and other autoimmune diseases.

Edwards JC, Cambridge G.

Nat Rev Immunol. 2006 May;6(5):394-403. Review.

PMID:
16622478
18.

B-cell depletion for rheumatic diseases: where are we?

Cohen SB.

MedGenMed. 2005 Jun 8;7(2):72. Review.

19.

Monoclonal antibodies in the treatment of systemic lupus erythematosus.

Robak E, Robak T.

Curr Drug Targets. 2009 Jan;10(1):26-37. Review.

PMID:
19149533
20.

B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.

Stübgen JP.

J Neuroimmunol. 2008 Nov 15;204(1-2):1-12. doi: 10.1016/j.jneuroim.2008.07.019. Review.

PMID:
18783837
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk